These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39127699)

  • 21. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis.
    Zhang H; Wang C; Fan J; Zhu Q; Feng Y; Pan J; Peng J; Shi J; Qi S; Liu Y
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12795. PubMed ID: 35156226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.
    Thimsen V; John N; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Knosp E; Losa M; Buslei R; Hölsken A
    Sci Rep; 2017 Nov; 7(1):15856. PubMed ID: 29158570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeted therapies in the medical management of craniopharyngioma.
    Iglesias P
    Pituitary; 2022 Jun; 25(3):383-392. PubMed ID: 35301645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
    Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
    Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic Control of Adamantinomatous Craniopharyngiomas.
    Marrero-Gutiérrez J; Bueno AC; Martins CS; Coeli-Lacchini FB; Silva-Júnior RMP; Marques Gonçalves GH; Ozaki JGO; de Almeida E Silva DC; Wildemberg LE; da Silva Antunes XL; Dos Santos AC; Machado HR; Santos MV; Moreira AC; Gadelha MR; Vêncio RZN; Antonini SRR; de Castro M
    J Clin Endocrinol Metab; 2024 Sep; 109(10):e1867-e1880. PubMed ID: 38181427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
    Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
    Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathology and pathogenesis of craniopharyngiomas.
    Larkin SJ; Ansorge O
    Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children.
    Gong J; Zhang H; Xing S; Li C; Ma Z; Jia G; Hu W
    Cancer Biomark; 2014; 14(4):241-51. PubMed ID: 24934367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
    Cao J; Lin JP; Yang LX; Chen K; Huang ZS
    Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The molecular pathogenesis of craniopharyngiomas.
    Campanini ML; Almeida JP; Martins CS; de Castro M
    Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
    Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
    J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
    Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
    Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
    Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
    Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
    Campanini ML; Colli LM; Paixao BM; Cabral TP; Amaral FC; Machado HR; Neder LS; Saggioro F; Moreira AC; Antonini SR; de Castro M
    Horm Cancer; 2010 Aug; 1(4):187-96. PubMed ID: 21761366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma.
    Li W; Zhang Y; Zhuang Y; Chen R; Xiong Z; Li K; Liu F; Xu H; Li D; Peng J
    Neuroendocrinology; 2024; 114(10):934-949. PubMed ID: 38964285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
    Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
    Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
    Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
    Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
    Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
    Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.